Cara Therapeutics Announces Positive Top-Line Results From Phase 2a Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Knee or Hip
09 déc. 2015 07h00 HE
|
Cara Therapeutics
Dose-related reduction observed in mean baseline pain score up to 34 percent after two weeks, with statistically significant reduction in mean rescue medication for top 5.0 mg dose
All four...
Cara Therapeutics to Present Poster at the ASHP 2015 Midyear Clinical Meeting
01 déc. 2015 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics to Webcast Presentation at the Piper Jaffray 27th Annual Healthcare Conference
25 nov. 2015 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 25, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics to Webcast Presentation at the Stifel 2015 Healthcare Conference
11 nov. 2015 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics Reports Third Quarter 2015 Financial Results
09 nov. 2015 16h01 HE
|
Cara Therapeutics
– Initiated Phase 3 program for I.V. CR845 in acute postoperative pain –
– Initiated Phase 2a trial of Oral CR845 in osteoarthritis patients –
– Earned $2.75M in...
Cara Therapeutics to Announce Third Quarter 2015 Financial Results on November 9, 2015
02 nov. 2015 16h30 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics to Present Late-Breaking Poster at Kidney Week 2015
29 oct. 2015 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference
26 oct. 2015 08h00 HE
|
Cara Therapeutics
Chief Medical Officer Dr. Joseph Stauffer to discuss potential for kappa opioids
SHELTON, Conn., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology...
Cara Therapeutics to Sponsor Symposium and Present Poster at ANESTHESIOLOGY 2015
19 oct. 2015 08h00 HE
|
Cara Therapeutics
Pain experts to discuss trends in kappa opioid receptor agonists and the future of postoperative pain management
Company to present positive data from Phase 2 acute pain trials of I.V....
Cara Therapeutics Achieves Milestone Payments From Japan and South Korea Partners for Development of CR845 in Uremic Pruritus
13 oct. 2015 08h00 HE
|
Cara Therapeutics
$2.5M Milestones Earned for Advancement of CR845 in Phase 2 Clinical Trials in U.S. and Japan
SHELTON, Conn., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a...